Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...

Molson Coors is buying a 8.5% stake in Fever-Tree for £71m as part of a long term partnership in the US, Liberation Labs ...

The Fed indeed cut rates in Q4, but stocks didn't jump as much as I anticipated ... But that won't get in the way of me giving it another shot. Here are my five predictions for the stock market ...

Benaim, a developer with 2,000 units under construction, says his work as an opera singer has prepared him for taking on the ...

Not long after the Illinois Department of Health announced the state’s overall respiratory illness cases had reached the ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

In the future Biotechnology may allows us repair, modify, or augment humans, but how will this be done? What will these ...

Underlying EBITDA and order intake beat should support Sartorius shares and those of its French subsidiary Sartorius Stedim Biotech on Tuesday, J.P.Morgan said in a note to clients. Shares in ...

Underlying EBITDA and order intake beat should support Sartorius shares and those of its French subsidiary Sartorius Stedim Biotech on Tuesday, J.P.Morgan said in a note to clients. Shares in ...

Also Read: Valneva’s Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults Data from this trial are also expected to support the ...

Lykos now needs a financial boost to stay afloat as it seeks another shot at approval ... and maintains a large minority stake in the biotech after it was spun out as a for-profit entity last ...